最新消息 - 昱厚生技股份有限公司

March 26, 2022

Safety Review Team Meeting Held for Cohort 2 (Mid-Dose Group) of New Drug AD17002-AI Trial; Expert Committee Approves Enrollment for Next Phase High-Dose Group.

Updates

March 15, 2022

【時報資訊】昱厚鼻噴新冠治療藥克服難關收治首位病患

Press

March 14, 2022

First Subject Enrolled in Phase IIa Clinical Trial of Investigational New Drug AD17002-SC for COVID-19.

Updates

March 14, 2022

【經濟日報】昱厚鼻噴新冠治療藥收首位病患啟動IIa期臨床試驗

Press

March 7, 2022

【環球生技月刊】台廠昱厚鼻噴劑、合一siRNA力拼新冠廣效、預防性投藥

Press

Company

Introduction

Team & Board of Directors

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Company

R&D Pipeline

Latest News

Safety Review Team Meeting Held for Cohort 2 (Mid-Dose Group) of New Drug AD17002-AI Trial; Expert Committee Approves Enrollment for Next Phase High-Dose Group.

【時報資訊】昱厚鼻噴新冠治療藥克服難關收治首位病患

First Subject Enrolled in Phase IIa Clinical Trial of Investigational New Drug AD17002-SC for COVID-19.

【經濟日報】昱厚鼻噴新冠治療藥收首位病患啟動IIa期臨床試驗

【環球生技月刊】台廠昱厚鼻噴劑、合一siRNA力拼新冠廣效、預防性投藥

Company

Introduction

Team & Board of Directors

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Company

R&D Pipeline

Latest News

Safety Review Team Meeting Held for Cohort 2 (Mid-Dose Group) of New Drug AD17002-AI Trial; Expert Committee Approves Enrollment for Next Phase High-Dose Group.

【時報資訊】昱厚鼻噴新冠治療藥克服難關 收治首位病患

First Subject Enrolled in Phase IIa Clinical Trial of Investigational New Drug AD17002-SC for COVID-19.

【經濟日報】昱厚鼻噴新冠治療藥收首位病患 啟動IIa期臨床試驗

【環球生技月刊】台廠昱厚鼻噴劑、合一siRNA力拼新冠廣效、預防性投藥

【時報資訊】昱厚鼻噴新冠治療藥克服難關收治首位病患

【經濟日報】昱厚鼻噴新冠治療藥收首位病患啟動IIa期臨床試驗